Kuchyne na miru

Global

Mar 20, 2019
Pharmaceutical Executive
Eli Lilly's Michael W. Magdycz discusses the ways in which country-level leaders approach governance and decision-making.
Mar 07, 2019
Pharmaceutical Executive
Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.
Feb 19, 2019
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Dr. Lingshi Tan, chairman and CEO of Shanghai-based CRO dMed Company Limited, discusses China's regulatory evolution and the opportunities to strengthen collaborations with FDA and other global agencies.
Feb 10, 2019
Pharmaceutical Executive
By
How innovation growth has upped the pressure on China to compete globally, forcing upgrades in regulatory, quality, and standards.
Feb 09, 2019
Pharmaceutical Executive
By
How the nation’s rapidly changing regulatory climate is creating a new landscape for pharmaceutical service providers.
Feb 06, 2019
Pharmaceutical Executive
What the new rules mean for Chinese-related investments and acquisitions in the US. By Peter Young.
Feb 06, 2019
Pharmaceutical Executive
Momentum and uncertainty shape the sector's economic picture. Michelle Maskaly reports.
Jan 30, 2019
You can’t make progress without consensus. This holds true for Brexit and for the unparalleled opportunity that the WHO Roadmap report on Access to Medicines and Vaccines presents, writes IFPMA's Greg Perry.
Jan 22, 2019
“You wanna play rough? Just try it!” was the gist of the New-Year message from the European pharma industry to the healthcare authorities circling around drug firms preparing for pricing discussions. Reflector reports.
Jan 08, 2019
While more are now achieving 100% compliance, life sciences companies are still grappling with implementation of the policy and procedure changes under the GDPR, writes Ashley Williams.
native1_300x100
best-cooler.reviews

https://yarema.ua

У нашей фирмы популярный портал про направление https://uniti.ua.
lorem ipsum